At a Glance
| Detail | Parambil | TrialView |
|---|---|---|
| Category | eDiscovery | eDiscovery |
| Total raised | $8M | $4.1M |
| Rounds tracked | 2 | 1 |
| Latest round | Seed, $6M · Jan 2026 | Growth, $4.1M · Nov 2025 |
| Last valuation | Not disclosed | Not disclosed |
| Lead investors | Bling Capital, Daybreak Ventures | Elkstone Ventures |
| Built for | Mid-size firms, Boutiques | Not disclosed |
| Headquarters | United States | Ireland |
Funding, Side by Side
Parambil rounds
- Jan 2026Seed$6M
- Jan 2025Seed$2M
TrialView rounds
- Nov 2025Growth$4.1M
Our Take
We have not tested these two head to head yet. The numbers above come from public funding announcements. If you use either one, tell us what you found and it may become a Field Note.
Quick Answers
- Which has raised more, Parambil or TrialView?
- Parambil has raised $8M in disclosed funding, compared with $4.1M for TrialView.
- Do Parambil and TrialView share investors?
- No. None of the investors we track have backed both companies.
- What is Parambil best for?
- Parambil is AI medical record review software for mass tort and complex litigation.
Source: Legal Tech Circle funding data, from public announcements. Updated November 10, 2026.